Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161

Benzinga Newsdesk www.benzinga.com Positive 80.8%

Neg 0% Neu 0% Pos 80.8%

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $150 to $161.